The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
A Dayton-area medical technology firm has recently had its AI-driven image processing and analysis technology cleared by the ...
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...
Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...
As part of its enforcement activities, the Food and Drug Administration sends warning letters to entities under its jurisdiction. Some letters are not ...
Oysters that came from one particular harvesting area in Louisiana and went to Walmart, Publix and other retailers have been recalled after sicknesses were reported in New Orleans during the weeks ...
The more complex and labor-intensive esoteric tests are reimbursed at a higher rate and often outsourced by hospitals to independent labs. Labcorp is funneling resources to broaden its menu of complex ...
Following a recall of grounding pads produced by Megadyne, a machinery industry company, the FDA is notifying veterinarians ...
A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback